Xeris Biopharma (XERS) Stock Price, News & Analysis

Company Overview

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company’s commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome. Xeris also markets Ogluo, a ready-to-use glucagon product in certain markets, and is developing additional medicines based on its formulation technologies.

Xeris was established in 2015 and expanded its portfolio through the acquisition of Strongbridge Biopharma in 2021. The company is headquartered in Chicago, Illinois, and serves patients primarily in the United States, with selected products available in international markets through commercial partners and regional arrangements. Its product portfolio addresses endocrinology, diabetes, rare diseases, and other specialty-care areas.

Key Stats

• Today's Range: $8.85 to $9.15
• 50-Day Range: $7.36 to $9.10
• 52-Week Range: $5.25 to $10.08
• Volume: 1.55 million shs
• Average Volume: 1.83 million shs
• Market Capitalization: $1.66 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.80
• Consensus Rating: Hold

Xeris Biopharma Stock Analysis - MarketRank™

Xeris Biopharma scored higher than 79% of companies evaluated by MarketBeat, and ranked 229th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Xeris Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Xeris Biopharma has a consensus price target of $12.80, representing about 40.7% upside from its current price of $9.10.

Amount of Analyst Coverage

Xeris Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 328.57%

Earnings Growth

Earnings for Xeris Biopharma are expected to grow by 328.57% in the coming year, from $0.07 to $0.30 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xeris Biopharma is -82.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xeris Biopharma is -82.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xeris Biopharma has a P/B Ratio of 113.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.62% of the float of Xeris Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Xeris Biopharma has a short interest ratio ("days to cover") of 4.83.

Change versus previous month

Short interest in Xeris Biopharma has recently increased by 0.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xeris Biopharma does not currently pay a dividend.

Dividend Growth

Xeris Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.67

News Sentiment

Xeris Biopharma has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

MarketBeat Follows

4 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,847,219.00 in company stock.

Percentage Held by Insiders

4.35% of the stock of Xeris Biopharma is held by insiders.

Percentage Held by Institutions

42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:XERS
• CIK: 1867096
• Web: www.xerispharma.com
• Phone: (844) 445-5704
• Fax: N/A
• Employees: 435
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xeris Biopharma: $12.80
• High Price Target: $18.00
• Low Price Target: $8.00
• Potential Upside/Downside: +40.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 130.00
• P/E Growth: N/A
• Net Income: $550 thousand
• Net Margins: -5.12%
• Pretax Margin: -5.12%
• Return on Equity: 338.21%
• Return on Assets: 3.50%

Debt

• Debt-to-Equity Ratio: 17.00
• Current Ratio: 1.45
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $335.41 million
• Price / Sales: 4.95
• Cash Flow: $0.10 per share
• Price / Cash Flow: 90.85
• Book Value: $0.08 per share
• Price / Book: 113.75

Miscellaneous

• Outstanding Shares: 182,320,000
• Free Float: 174,389,000
• Market Cap: $1.66 billion
• Optionable: Optionable
• Beta: 0.70